Last reviewed · How we verify
RT plus Cisplatin
RT plus Cisplatin works by combining radiation therapy with a chemotherapy drug to kill cancer cells.
RT plus Cisplatin works by combining radiation therapy with a chemotherapy drug to kill cancer cells. Used for Non-small cell lung cancer, Ovarian cancer, Testicular cancer.
At a glance
| Generic name | RT plus Cisplatin |
|---|---|
| Also known as | Cisplatin |
| Sponsor | Sun Yat-sen University |
| Drug class | Cytotoxic chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Radiation therapy (RT) uses high-energy rays to damage cancer cells' DNA, while Cisplatin is a chemotherapy drug that interferes with DNA replication, causing cancer cells to die. The combination of both treatments can be more effective than either one alone.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
- Testicular cancer
Common side effects
- Nausea
- Vomiting
- Fatigue
- Hair loss
- Diarrhea
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer (PHASE1)
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RT plus Cisplatin CI brief — competitive landscape report
- RT plus Cisplatin updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI